Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.

“Dupilumab appears promising as a steroid-sparing treatment of ADC-induced cutaneous toxicities,” which “are difficult to ...

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Among patients with severe asthma receiving dupilumab for 12 months, 91% had a clinical response and 30% achieved clinical remission.

Inhalable Biologics Market Explosive 16.2% CAGR forecast for inhalable biologics market, fueled by innovation and patient demand for non-in ...

As patent cliffs approach and new mechanisms gain ground, COPD drugs like HRS-9821 are fast becoming coveted assets.

Review compares patient-important outcomes and assesses evidence among 42 systemic treatments in patients in 93 studies.

Dupilumab治疗COPD的2型炎症生物标志物分析：BOREAS III期试验的预测价值与动态变化 《The Lancet Respiratory Medicine》：Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a ...

Discover a study that highlights dupilumab’s consistent efficacy in eosinophilic oesophagitis, even among patients with previous treatment failure or intolerance.

Sanofi rode the growing sales wave for blockbuster immunology drug Dupixent (dupilumab) in Q2 but reported ...

This study could potentially impact the stock performance of Regeneron Pharmaceuticals and Sanofi, as positive results may enhance investor sentiment and market valuation. The study’s focus on COPD, a ...